SEC Form 4	
------------	--

Instruction 1(b)

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 193/

OMB APPROVAL

OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

	( )			or Section 30(h) of the Investment Company Act of 1940		-				
1. Name and Address of Reporting Ferson			0	2. Issuer Name <b>and</b> Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Shanmugam Muthusamy</u>		<u>ny</u>		X	Director	10% Owner				
(Last)		(First)	(Middle)	One of Earliest Transaction (Month/Day/Year)	x	Officer (give title below)	Other (specify below)			
l` ´	C/O ANI PHARMACEUTICALS, INC.			03/17/2022	HEAD OF R&D, COO-NOVITIUM C					
210 MA	IN STF	REET WEST	Γ							
(Street)				4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line)	vidual or Joint/Group F	iling (Check Applicable			
BAUDE	TTE	MN	56623		X	Form filed by One R	1 0			
		(2) ( )				Form filed by More t Person	nan One Reporting			
(City)		(State)	(Zip)							

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

· ··· · · · · · · · · · · · · · · · ·											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Disposed Of	s Acquire f (D) (Inst	d (A) or tr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)	
Common Stock	03/17/2022		Р		5,000	A	\$27.6503 <sup>(1)</sup>	18,460	D		
Common Stock	03/17/2022		Р		5,000	A	\$27.6503 <sup>(1)</sup>	5,000	I	Held by SS Pharma LLC <sup>(2)</sup>	
Common Stock								1,332,620	I	Held by Esjay LLC <sup>(3)</sup>	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instr and S	Expiration Date (Month/Day/Year) rised rssed		piration Date Amount of		Amount of Securities Underlying Derivative Security (Instr. 5) Security Owned Security (Instr. 5) Security Owned Following a and 4)		derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The shares were acquired in multiple trades at prices ranging from \$27.36 to \$28.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

2. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

3. The Reporting Person holds voting and dispositive power over the shares held by Esjay LLC.

/s/ Muthusamy Shanmugam 03/21/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.